Presenting at the Annual Immuno-Oncology Summit

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that it will be presenting at the 8th Immuno-Oncology Summit Europe 2024. The Immuno-Oncology Summit Europe is a world-class event for professionals dedicated to showcasing advancements and innovations in immuno-oncology for breakthrough therapies, and is being held from 23-25 April 2024 in London, UK.

Professor Lindy Durrant, Chief Executive Officer of Scancell, will be speaking in the "Therapeutic Cancer Vaccines" program, where emphasis on clinical studies will be highlighted as part of a broader collection of talks furthering understanding of immunological mechanisms of action, dosing and delivery strategies as well as how such products can be combined with checkpoint inhibitors. Her talk, titled "Clinical Update on the DC Targeting Melanoma Vaccine, SCIB1 and The Modi-1 Vaccine Targeting Citrullination" will take place from 2:45 pm - 3:15 pm BST on Tuesday 23 April 2024.

Professor Lindy Durrant, Chief Executive Officer of Scancell, said: "I am pleased to be invited to share this exciting data on SCIB1, Scancell's 'off the shelf' ImmunoBody® cancer vaccine, which has demonstrated positive efficacy data from the Phase 2 SCOPE trial for advanced unresectable melanoma. I am also looking forward to presenting early data from patients receiving Modi-1 as a monotherapy in range of hard-to-treat solid tumours, which has shown good T cell responses, safety and tolerability. Following on from AACR, there has been significant interest in the clinical development of therapeutic cancer vaccines, and I am excited to demonstrate the progress Scancell has made in this class of immunotherapies."